文献速递治疗药物监测与药物基因组学特殊人群用药

药物代谢组学在活体肾供者与肾移植受者尿中检出多种未报道的美托洛尔代谢物

Pharmacometabolomics Detects Various Unreported Metoprolol Metabolites in Urine of (Potential) Living Kidney Donors and Kidney Transplant Recipients.
PubMed 文献 · Clin Pharmacokinet · 2025-04-26

本研究利用现有液相色谱-高分辨质谱药物代谢组学数据,在18例(潜在)活体肾供者和374例肾移植受者中分析美托洛尔代谢物。除确认7种预期代谢物外,还检出多种未报道代谢物,包括美托洛尔苯甲酸及9种未知代谢物,两组代谢物谱无差异。

要点

  • 在真实世界人群中检出多种既往未报道的美托洛尔代谢物
  • 潜在活体肾供者与肾移植受者的美托洛尔代谢物谱无差异
  • 结果提示需重复研究并评估药物遗传学检测以优化美托洛尔治疗

核心结论

  • 检出的美托洛尔代谢物数量多于既往报道,提示需开展重复研究并评估药物遗传学检测方法以实现更安全有效的美托洛尔治疗。

研究设计与样本

  • 基于移植线食品与营养生物样本库和队列研究(NCT02811835)的现有液相色谱-高分辨质谱药物代谢组学数据,对18例(潜在)活体肾供者和374例肾移植受者进行美托洛尔真实世界药物代谢研究。

主要发现

  • 在两组中均确认了7种预期代谢物,包括高丰度的美托洛尔酸和羟基美托洛尔。
  • 未能检出去异丙基美托洛尔和名为「H 119/68」的代谢物。
  • 检出了去异丙基美托洛尔的预期变体(伯胺去除后剩余甲基氧化为羧酸,即「H 104/83」)和一种未知/未报道的美托洛尔代谢物「美托洛尔苯甲酸」。
  • 还检出9种其他既往未知/未报道的代谢物,推测为N-葡萄糖醛酸化美托洛尔、4种羟基美托洛尔的葡萄糖醛酸化版本,以及美托洛尔酸的甲酰化、葡萄糖醛酸化和2种羟基化版本。
  • 潜在活体肾供者和肾移植受者中检出相同代谢物,主成分分析显示两组代谢物谱无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Metoprolol is primarily metabolized via the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme, which underlies interindividual variation in conversion rates and may benefit from pharmacogenetics-driven therapy personalization. However, the field relies heavily on knowledge of a drug's metabolism, often originating from early-phase clinical trials with single-dose administration in small samples of healthy volunteers. Pharmacogenetics could thus benefit from real-world drug metabolism studies. METHODS: We conducted a real-world drug metabolism study for metoprolol in 18 (potential) living kidney donors and 374 kidney transplant recipients from the Transplant Lines Food and Nutrition Biobank and Cohort Study (NCT02811835) using existing liquid chromatography-high resolution mass spectrometry pharmacometabolomic data. RESULTS: In both groups, we confirmed the presence of seven expected metabolites, including the high-abundance substances metoprolol acid and hydroxymetoprolol. We were unable to detect deisopropylmetoprolol and a metabolite known as "H 119/68". However, we did find putative further oxidized forms, namely the expected variant of deisopropylmetoprolol in which the primary amine is removed and the leftover methyl group is oxidized into a carboxylic acid ("H 104/83") and an unknown/unreported metoprolol metabolite that we refer to as "metoprolol benzoic acid". Moreover, we found nine other previously unknown/unreported metabolites, putatively reflecting N-glucuronidated metoprolol, four glucuronidated versions of hydroxymetoprolol, and a formylated, a glucuronidated, and two hydroxylated versions of metoprolol acid. Interestingly, the same metabolites were detected in potential living kidney donors and kidney transplant recipients, and metabolite profiles did not differ between both groups in principal component analysis. CONCLUSION: We found more metoprolol metabolites than previously reported, calling for replication studies and evaluation of pharmacogenetic testing approaches to realize safer, more effective metoprolol therapy.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Heddema WA, Hof MAJ, Sosnowski P, et al. Pharmacometabolomics Detects Various Unreported Metoprolol Metabolites in Urine of (Potential) Living Kidney Donors and Kidney Transplant Recipients. Clin Pharmacokinet. 2025. PMID: 40285825. doi:10.1007/s40262-025-01502-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。